Cormedix Completes Enrollment for Phase III Rezzayo Trial
Enrollment is complete in the global Phase III ReSPECT study testing once‑weekly rezafungin for prophylaxis of Candida, Aspergillus, and...
Positive Interim Phase 2 Data for Artelo’s ART27.13 Drug
Interim data from the Phase 2 CAReS trial showed that patients titrated to the highest dose of ART27.13 (1,300...
New Phase 3 Data for CAN-2409 in Prostate Cancer at ASTRO
CAN-2409 improved disease-free survival by 30% versus placebo in a 745-patient Phase 3 trial in intermediate-to-high-risk localized prostate cancer...
Pioneering Pancreatic Cancer Trial Launched by Elicio, MSK
Updated Phase 1 data from Elicio’s AMPLIFY-201 program reported a 16.3-month median recurrence-free survival and 28.9-month median overall survival...
Why Correcting Trial Imaging Errors at Central Review Is Too Late—and Too Expensive
The patient drove two hours each way for the trial, which her oncologist and she believed was her best...
Clinuvel’s Novel Formulations Advance in Preclinical Program
CLINUVEL has advanced a portfolio of sustained‑release liquid depot formulations for peptides into preclinical testing, targeting predictable release kinetics...
Northwell Christina Brennan on Future of Site-Sponsor Partnerships
At the Veeva R&D and Quality Summit in Boston, we interviewed Dr. Christina Brennan, Senior Vice President of Clinical...
Breakthrough: NIH Funds Alzheimer’s Drug AD04 with $2.5M
ADvantage Therapeutics secured a $2.5 million Phase II SBIR grant from the National Institute on Aging to advance AD04,...
Immuneering to Discuss Pancreatic Cancer Survival Data
Updated overall survival and safety data from a 34‑patient, first‑line pancreatic cancer cohort treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel...
Groundbreaking Data: Revita Maintains Weight Loss Post-GLP-1
In a randomized, double-blind, sham-controlled midpoint cohort of REMAIN-1 (N=45), Revita produced an additional 2.5% total body weight loss...